In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

Refining the long-term prognostic value of hybrid PET/CT through machine learning

Session Young Investigator Awards

Speaker Luis Eduardo Juarez-Orozco

Congress : ICNC, Nuclear Cardiology & Cardiac CT 2019

  • Topic : imaging
  • Sub-topic : Hybrid and Fusion Imaging
  • Session type : Young Investigator Award Abstracts
  • FP Number : 10

Authors : L E Juarez-Orozco (Turku,FI), T Maaniitty (Turku,FI), JW Benjamins (Groningen,NL), MA Niemi (Turku,FI), P Van Der Harst (Groningen,NL), A Saraste (Turku,FI), J Knuuti (Turku,FI)

Authors:
L E Juarez-Orozco1 , T Maaniitty2 , JW Benjamins3 , MA Niemi2 , P Van Der Harst3 , A Saraste2 , J Knuuti2 , 1Turku PET Centre - Turku - Finland , 2Turku University Hospital, PET Center - Turku - Finland , 3University Medical Center Groningen, Cardiology - Groningen - Netherlands (The) ,

Citation:

Background

Machine Learning (ML) is revolutionizing medical data analysis. ML algorithms offer the possibility to evaluate large numbers of interrelated variables to predict CAD-related outcomes. Sequential hybrid imaging with PET/CCTA has demonstrated diagnostic and prognostic value in patients with suspected CAD. However, traditional prognostic analyses may be unable to exploit the full potential the resulting structured clinical, CCTA and PET data. Therefore, we aimed to implement a sequential ML workflow to analyze clinical and hybrid PET/CT data for the identification of patients who developed myocardial infarction (MI) or death in a long-term follow up registry.

Methods

Data from 951 symptomatic patients with an intermediate risk of CAD was analyzed. Patients underwent sequential hybrid 15O-water PET/CCTA and were followed for an average of 6 years for the development of MI or cardiac death. Clinical variables were extracted from the electronic patient records (sex, age, smoking, diabetes, hypertension, dyslipidemia, family history, chest complaints, dyspnea and early revascularization). CCTA images were evaluated for system dominance and segmentally for: presence of atherosclerotic plaque, % of luminal stenosis and plaque calcification. Thereon, absolute stress PET myocardial perfusion data was evaluated regionally (ml/g/min). After feature selection, modeling was conducted utilizing a 10-fold cross validated boosted ensembles approach (LogitBoost) to analyze clinical, PET and CCTA data. Predictive performance for the development of MI or death was evaluated through AUCs and accuracy.

Results

There were 525 women (55%). Mean age was 61±9 years. 24 MI and 49 all-cause deaths were documented during follow-up (range: 1 month – 9.6 years), while 109 patients underwent early revascularization. With a total of 85 variables (10 clinical, 58 from CCTA and 17 from PET) analyzed, predictive performance was discrete for clinical data (AUC=0.65,Acc=90%) and moderate for clinical + quantitative PET data (AUC=0.69,Acc=92.5%), while there was significant performance improvement (p=0.005) when integrating clinical + quantitative PET + CTA data (AUC=0.82,Acc=95.4%) in the identification of patients who experienced MI or all-cause death during follow up independently from early revascularization.

Conclusion

Stepwise ML for the analysis of clinical and hybrid sequential cardiac PET/CCTA data can improve the identification of symptomatic patients with suspected CAD who will develop MI or death in long-term follow up. This proposes the added prognostic value of ML in cardiac hybrid imaging.

This content is currently on FREE ACCESS

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are